Comparison of Two Phase II Trials of Neoadjuvant Temozolomide Followed with Concomitant and Adjuvant Temozolomide and Hypofractionated Accelerated Radiotherapy with or without Metformin in Patients with Newly Diagnosed Glioblastoma

被引：0
|
作者：
Shenouda, G. [1 ]
Petrecca, K. [2 ]
Abdulkarim, B. S. [3 ]
Owen, S. [1 ]
Panet-Raymond, V. [3 ]
Diaz, R. [4 ]
Guiot, M. C. [5 ]
Carvalho, T. [6 ]
Charbonneau, M. [1 ]
Hall, J. [7 ]
Souhami, L.
机构：
[1] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[2] McGill Univ, Neurosurg, Montreal, PQ, Canada
[3] McGill Univ, Ctr Hlth, Dept Radiat Oncol, Montreal, PQ, Canada
[4] Montreal Neurol Hosp, Montreal, PQ, Canada
[5] Montreal Neurol Inst Hosp, Dept Pathol, Montreal, PQ, Canada
[6] McGill Univ, Montreal, PQ, Canada
[7] Montreal Neurol Hosp, Montreal, PQ, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
211
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [41] Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
    Kim, Byung Sup
    Seol, Ho Jun
    Nam, Do-Hyun
    Park, Chul-Kee
    Kim, Il Han
    Kim, Tae Min
    Kim, Jeong Hoon
    Cho, Young Hyun
    Yoon, Sang Min
    Chang, Jong Hee
    Kang, Seok-Gu
    Kim, Eui Hyun
    Suh, Chang-Ok
    Jung, Tae-Young
    Lee, Kyung-Hwa
    Kim, Chae-Yong
    Kim, In Ah
    Hong, Chang-Ki
    Yoo, Heon
    Kim, Jin Hee
    Kang, Shin-Hyuk
    Kang, Min Kyu
    Kim, Eun-Young
    Kim, Sun-Hwan
    Chung, Dong-Sup
    Hwang, Sun-Chul
    Song, Joon-Ho
    Cho, Sung Jin
    Lee, Sun-Il
    Lee, Youn-Soo
    Ahn, Kook-Jin
    Kim, Se Hoon
    Lim, Do Hun
    Gwak, Ho-Shin
    Lee, Se-Hoon
    Hong, Yong-Kil
    [J]. CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 193 - 203
  • [42] Radiotherapy, temozolomide, and bevacizumab followed by irinotecan, temozolomide and bevacizumab in newly diagnosed glioblastoma multiforme: Preliminary results front an ongoing phase II trial
    Kirkpatrick, J. P.
    Desjardins, A.
    Reardon, D. A.
    Vredenburgh, J. J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S209 - S209
  • [43] Radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma (vol 352, pg 19, 2005)
    Stupp, R
    Mason, WP
    van den Beuf, MJ
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (06) : 949 - 949
  • [44] Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)
    Beal, K.
    Omuro, A.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Yamada, Y.
    Abrey, L. E.
    Gutin, P. H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S129 - S129
  • [45] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. M. P.
    Beal, K.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Gavrilovic, I. T.
    Nolan, C.
    Hormigo, A.
    Lassman, A. B.
    Kaley, T. J.
    Mellinghoff, I. K.
    Grommes, C.
    Panageas, K.
    Reiner, A. S.
    Barradas, R.
    Abrey, L. E.
    Gutin, P. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis
    Erpolat, Ozge Petek
    Akmansu, Muge
    Goksel, Fatih
    Bora, Huseyin
    Yaman, Emel
    Buyukberber, Suleyman
    [J]. TUMORI JOURNAL, 2009, 95 (02): : 191 - 197
  • [48] PHASE II RANDOMIZED TRIAL OF SHORT COURSE HYPOFRACTIONATED RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA
    Madan, R.
    Thakur, S.
    Salunke, P.
    Ahuja, C.
    Khosla, D.
    Yadav, B. S.
    Kapoor, R.
    Kumar, N.
    [J]. NEURO-ONCOLOGY, 2019, 21 : 67 - 67
  • [49] Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM)
    Stupp, R.
    Goldbrunner, R.
    Neyns, B.
    Schlegel, U.
    Clement, P.
    Grabenbauer, G. G.
    Hegi, E.
    Nippgen, J.
    Picard, M.
    Weller, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] A PHASE I STUDY OF AT-101 PLUS RADIOTHERAPY AND TEMOZOLOMIDE AND AT-101 PLUS ADJUVANT TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Fiveash, John
    Nabors, Louis B.
    Mikkelsen, Tom
    Peereboom, David M.
    Lesser, Glenn J.
    Chowdhary, Sajeel A.
    Grossman, Stuart
    Ye, Xiaubu
    Leopold, Lance
    Rosenfeld, Myrna
    [J]. NEURO-ONCOLOGY, 2009, 11 (05) : 666 - 666
12345